At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Breast scan using the Z-scanner (device), Breast scan using the Z-scanner (device)
- How long the study runs
- Study runs about 11 months (dates as stated)
- About the drug or intervention
- Breast scan using the Z-scanner — device: Four repeated scans of both breasts using the Z-scanner. · Breast scan using the Z-scanner — device: A scan of both breasts using the Z-scanner.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- Female
- Number of participants
- 90
- Started
- 2024-01-25
- Last checked
- 2024-06
Plain English Summary
What is this study?
- • Testing a new treatment for breast cancer
- • Clinical study - 90 participants
- • The goal of this observational study is to investigate the ability of a the Z-scanner to identify and differentiate cancer and benign lesions from healthy breast tissue based on permittivity
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with breast cancer
- • Female only
Where?
- • London - Imperial College Healthcare NHS Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The goal of this observational study is to investigate the ability of a the Z-scanner to identify and differentiate cancer and benign lesions from healthy breast tissue based on permittivity. The main questions it aims to answer are: 1. Determine the permittivity values of the Z-scanner associated with healthy, benign, and malignant tissue in human breasts. 2. Determine the repeatability, reproducibility, inter-and intra-operator variability of the Z-scanner.
More detail
Permittivity is the measure of a material's ability to store electrical energy in the electric field. Different materials are known to have different permittivity including the human body. Research is looking into utilising permittivity differences in the human body to detect cancer. There is a particular focus in breast cancer because it is the most common type of cancer in women globally, and research has shown that permittivity of healthy breast tissue is different to cancer tissue. Furthermore, breast tissue can be easily accessible by non-invasive means and has well-established tools available to support cancer detection. However, results from many studies vary greatly and more research is needed to understand how permittivity can be used in cancer research. Zedsen Limited has developed a permittivity measuring device (Z-scanner) capable of measuring a material's permittivity. The purpose of this study is to establish the permittivity of healthy, benign, and cancer tissue associated with the Z-scanner. 90 women attending a routine screening assessment clinic or a one stop clinic at Charing Cross Hospital will be recruited over the course of a year. The study is split into 2 parts. Part A will recruit 20 participants to assess whether scanner results can be repeated and reproduced by different users and hardware. Part B will recruit 70 participants to assess whether the Z-scanner can differentiate between benign and cancerous lesion. All participants will have both their breasts scanned using the Z-scanner during their routine appointment. This allows us to investigate the ability of the Z-scanner to identify and differentiate benign and cancerous lesions from healthy breast tissue based on permittivity. Results from this study can further our understanding on how permittivity and such devices can be used in cancer research.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: Female only
What the study is looking for
- ✓Attending a causing symptoms clinic or other appointment at a participating breast clinic site
- ✓Assigned female sex at time of birth
- ✓Aged 18 years or older at time of scan
- ✓Willing, able and mentally competent to read, understand, and provided agreement to take part in English
Who cannot take part
- ✗Participants who have undergone biopsy less than 14 days before the Z-scanner scan
- ✗Participants with implanted electronics
- ✗Participants with breast implants
- ✗Participants with nipple piercings (unless they are removed prior to the scan)
- ✗Participants who are lactating
See the full criteria
Where Is This Study? (1 UK site)
Imperial College Healthcare NHS Trust
London, United Kingdom
How to Get in Touch
Jessica Lin
Sponsor contactCONTACT
